Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.46 |
| ▸ | HPGD | P15428 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | USP2 | O75604 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12569243 | 0.84 | ALDH1A1 (0.48) | ALDH1A1HPGDKDM4EHSD17B10MAPT | |
| SCHEMBL5383271 | 0.81 | ALDH1A1 (0.48) | ALDH1A1HPGDKDM4EHSD17B10MAPT | |
| SCHEMBL12569246 | 0.81 | ALDH1A1 (0.48) | ALDH1A1HPGDKDM4EHSD17B10MAPT | |
| SCHEMBL13019204 | 0.81 | ALDH1A1 (0.56) | ALDH1A1HPGDKDM4EHSD17B10MAPT | |
| SCHEMBL5382388 | 0.81 | ALDH1A1 (0.46) | ALDH1A1HPGDKDM4EHSD17B10MAPT | |
| SCHEMBL5383266 | 0.80 | HTT (0.46) | ALDH1A1HPGDKDM4EHSD17B10MAPT | |
| SCHEMBL13019203 | 0.80 | ALDH1A1 (0.57) | ALDH1A1HPGDKDM4EHSD17B10MAPT | |
| SCHEMBL5907247 | 0.71 | ALDH1A1 (0.56) | ALDH1A1HPGDKDM4EHSD17B10MAPT | |
| SCHEMBL3836461 | 0.71 | SMN1; SMN2 (0.44) | ALDH1A1HPGDKDM4EHSD17B10MAPT | |
| SCHEMBL5390665 | 0.70 | TP53 (0.47) | ALDH1A1KDM4EMAPTGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235575-B2 | Guanidine mimics as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-06-26 | — | — | US | disclosed |
| US-20060040973-A1 | 1-Aminoisoindolyl derivatives and 3-amino- and 3-hydroxy- indazolyl-, benzisoxazolyl, and benzisothiazolyl- derivatives, e.g., 3-(3'-Aminobenzisoxazol-5'-yl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]-5-methylisoxazoline; treating thromboembolic disorders | LAM PATRICK Y | 2006-02-23 | — | — | US | disclosed |
| US-6958356-B2 | Guanidine mimics factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-25 | — | — | US | disclosed |
| EP-0991638-B1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-08-17 | — | — | EP | disclosed |
| US-6906070-B2 | Anticoagulants | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-20030069258-A1 | Novel guanidine mimics factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-10 | — | — | US | disclosed |
| US-20020025963-A1 | Novel guanidine mimics as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-28 | — | — | US | disclosed |
| US-6339099-B1 | FOR THERAPY AND PROPHYLAXIS OF THROMBOEMBOLIC DISORDER | DUPONT PHARMACEUTICALS COMPANY | 2002-01-15 | — | — | US | disclosed |
| EP-0991638-A1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998057951-A1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040973-A1 | 1-Aminoisoindolyl derivatives and 3-amino- and 3-hydroxy- indazolyl-, benzisoxazolyl, and benzisothiazolyl- derivatives, e.g., 3-(3'-Aminobenzisoxazol-5'-yl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]-5-methylisoxazoline; treating thromboembolic disorders | SERPINC1, F7, SERPINE1 | ALDH1A1 606/4885HPGD 2057/4885KDM4E 232/4885 |
| US-20030069258-A1 | Novel guanidine mimics factor Xa inhibitors | TFPI, F11, F12 | ALDH1A1 2218/4885HPGD 1434/4885KDM4E 396/4885 |
| US-20020025963-A1 | Novel guanidine mimics as factor Xa inhibitors | F11, SERPINC1, TFPI | ALDH1A1 1803/4885HPGD 1415/4885KDM4E 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.